KRAS and colorectal carcinoma: An sDNA test approved by Food and Drug Administration (FDA), containing multiple DNA test (KRAS mutations and NDRG4 and BMP3 hypermethylation) and fecal hemoglobin, was validated with 92% sensitivity of CRC.